2PN9 - Header Asymmetric Unit

HEADER RNA 24-APR-07 2PN9

TITLE NMR STRUCTURE OF A KISSING COMPLEX FORMED BETWEEN THE TAR TITLE 2 RNA ELEMENT OF HIV-1 AND A LNA MODIFIED APTAMER

COMPND MOL_ID: 1; COMPND 2 MOLECULE: 5'- COMPND 3 R(*GP*GP*AP*GP*CP*CP*UP*GP*GP*GP*AP*GP*CP*UP*CP*C)-3'; COMPND 4 CHAIN: A; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: RNA 16-MER WITH LOCKED RESIDUES 9-10; COMPND 8 CHAIN: B; COMPND 9 ENGINEERED: YES

SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: RNA WAS PREPARED BY IN VITRO TRANSCRIPTION SOURCE 4 WITH T7 RNA POLYMERASE; SOURCE 5 MOL_ID: 2; SOURCE 6 SYNTHETIC: YES; SOURCE 7 OTHER_DETAILS: APTAMER WAS PURCHASED FROM EUROGENTEC

KEYWDS RNA; LNA; LOCKED NUCLEIC ACID; NMR; APTAMER; TAR; HIV-1; KEYWDS 2 KISSING

EXPDTA SOLUTION NMR

NUMMDL 10

AUTHOR I.LEBARS,T.RICHARD,C.DI PRIMO,J.-J.TOULME

REVDAT 2 24-FEB-09 2PN9 1 VERSN REVDAT 1 30-OCT-07 2PN9 0

JRNL AUTH I.LEBARS,T.RICHARD,C.DI PRIMO,J.-J.TOULME JRNL TITL NMR STRUCTURE OF A KISSING COMPLEX FORMED BETWEEN JRNL TITL 2 THE TAR RNA ELEMENT OF HIV-1 AND A LNA-MODIFIED JRNL TITL 3 APTAMER JRNL REF NUCLEIC ACIDS RES. V. 35 6103 2007 JRNL REFN ISSN 0305-1048 JRNL PMID 17768146 JRNL DOI 10.1093/NAR/GKM655

REMARK 1

REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.

REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER A. T. ETALL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL

REMARK 4 REMARK 4 2PN9 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08

REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 14-MAY-07. REMARK 100 THE RCSB ID CODE IS RCSB042566.

REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 288; 277 REMARK 210 PH : 6.4; 6.4 REMARK 210 IONIC STRENGTH : NULL; NULL REMARK 210 PRESSURE : AMBIENT; AMBIENT REMARK 210 SAMPLE CONTENTS : 1 MM UNLABELED TAR; 1 MM REMARK 210 UNLABELED APTAMER; 1 MM REMARK 210 UNLABELED TAR/APTAMER COMPLEX; REMARK 210 1 MM UNLABELED TAR/APTAMER REMARK 210 COMPLEX; 1 MM 15N/13C LABELED REMARK 210 TAR/UNLABELED APTAMER COMPLEX; REMARK 210 1 MM 15N/13C LABELED TAR/ REMARK 210 UNLABELED APTAMER COMPLEX REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : HSQC, 3D HCCH-TOCSY, 2D REMARK 210 NOESY, 2D TOCSY, 3D NOESY-NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 500 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : CNS 1.1 REMARK 210 METHOD USED : NULL REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 10 REMARK 210 CONFORMERS, SELECTION CRITERIA : THE SUBMITTED STRUCTURE ARE REMARK 210 THE 10 STRUCTURES WITH ZERO REMARK 210 VIOLATION ON NOE DISTANCE, REMARK 210 DIHEDRAL AND WITH THE LOWEST REMARK 210 ENERGY. REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: THE STRUCTURE WAS DETERMINED USING STANDARD HOMONULEAR REMARK 210 AND HETERONUCLEAR METHODS.

REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS.

REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.

REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000

DBREF 2PN9 A 1 16 PDB 2PN9 2PN9 1 16 DBREF 2PN9 B 17 32 PDB 2PN9 2PN9 17 32

SEQRES 1 A 16 G G A G C C U G G G A G C SEQRES 2 A 16 U C C SEQRES 1 B 16 C A C G G U C C 10C LCA G A C SEQRES 2 B 16 G U G

MODRES 2PN9 10C B 25 C MODRES 2PN9 LCA B 26 A

HET 10C B 25 32 HET LCA B 26 34

HETNAM 10C 4-AMINO-1-{2,5-ANHYDRO-4-[(PHOSPHONOOXY)METHYL]-ALPHA- HETNAM 2 10C L-LYXOFURANOSYL}PYRIMIDIN-2(1H)-ONE HETNAM LCA [(1R,3R,4R,7S)-7-HYDROXY-3-(ADENIN-9-YL)-2,5- HETNAM 2 LCA DIOXABICYCLO[2.2.1]HEPT-1-YL]METHYL DIHYDROGEN HETNAM 3 LCA PHOSPHATE

FORMUL 2 10C C10 H14 N3 O8 P FORMUL 2 LCA C11 H14 N5 O7 P

LINK O3' C B 24 P 10C B 25 1555 1555 1.61 LINK O3' 10C B 25 P LCA B 26 1555 1555 1.61 LINK O3' LCA B 26 P G B 27 1555 1555 1.61

CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1

ORIGX1 1.000000 0.000000 0.000000 0.00000

ORIGX2 0.000000 1.000000 0.000000 0.00000

ORIGX3 0.000000 0.000000 1.000000 0.00000

SCALE1 1.000000 0.000000 0.000000 0.00000

SCALE2 0.000000 1.000000 0.000000 0.00000

SCALE3 0.000000 0.000000 1.000000 0.00000